Terns Pharmaceuticals Inc
NASDAQ:TERN

Watchlist Manager
Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc
NASDAQ:TERN
Watchlist
Price: 7.17 USD 12.74%
Market Cap: 609m USD
Have any thoughts about
Terns Pharmaceuticals Inc?
Write Note

Terns Pharmaceuticals Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Terns Pharmaceuticals Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Terns Pharmaceuticals Inc
NASDAQ:TERN
Cash from Investing Activities
-$38m
CAGR 3-Years
N/A
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Investing Activities
-$18.5B
CAGR 3-Years
-18%
CAGR 5-Years
-48%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Investing Activities
-$22.5B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash from Investing Activities
-$3.8B
CAGR 3-Years
31%
CAGR 5-Years
-15%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Cash from Investing Activities
-$6.2B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Cash from Investing Activities
-$10.3B
CAGR 3-Years
-50%
CAGR 5-Years
-3%
CAGR 10-Years
-13%
No Stocks Found

Terns Pharmaceuticals Inc
Glance View

Market Cap
608.9m USD
Industry
Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

TERN Intrinsic Value
3.1 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Terns Pharmaceuticals Inc's Cash from Investing Activities?
Cash from Investing Activities
-38m USD

Based on the financial report for Dec 31, 2023, Terns Pharmaceuticals Inc's Cash from Investing Activities amounts to -38m USD.

What is Terns Pharmaceuticals Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-51%

Over the last year, the Cash from Investing Activities growth was -71%.

Back to Top